Alkermes Full Year 2023 Earnings: Beats Expectations
Alkermes (NASDAQ:ALKS) Full Year 2023 Results
Key Financial Results
Revenue: US$1.66b (up 50% from FY 2022).
Net income: US$519.2m (up from US$158.3m loss in FY 2022).
Profit margin: 31% (up from net loss in FY 2022). The move to profitability was primarily driven by higher revenue.
EPS: US$3.12 (up from US$0.97 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Alkermes Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 1.7%. Earnings per share (EPS) also surpassed analyst estimates by 35%.
Looking ahead, revenue is expected to decline by 1.1% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 17%.
Performance of the American Biotechs industry.
The company's shares are up 18% from a week ago.
Risk Analysis
Before you take the next step you should know about the 1 warning sign for Alkermes that we have uncovered.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
